113 related articles for article (PubMed ID: 16818714)
1. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
Marsh S; King CR; McLeod HL; Paul J; Gifford G; Brown R
Clin Cancer Res; 2006 Jul; 12(13):4127; author reply 4127-9. PubMed ID: 16818714
[No Abstract] [Full Text] [Related]
2. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE; Beesley J; Paul J; Fereday S; Spurdle AB; Webb PM; Byth K; Marsh S; McLeod H; ; Harnett PR; Brown R; DeFazio A; Chenevix-Trench G
Clin Cancer Res; 2008 Sep; 14(17):5594-601. PubMed ID: 18765553
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
J Pharm Sci; 2008 Jun; 97(6):2045-8. PubMed ID: 17828752
[TBL] [Abstract][Full Text] [Related]
4. Optimizing primary chemotherapy in ovarian cancer.
Markman M
Hematol Oncol Clin North Am; 2003 Aug; 17(4):957-68, viii. PubMed ID: 12959185
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Björn N; Jakobsen Falk I; Vergote I; Gréen H
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):277-287. PubMed ID: 29504705
[TBL] [Abstract][Full Text] [Related]
6. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
Bolis G; Scarfone G; Raspagliesi F; Mangili G; Danese S; Scollo P; Lo Russo D; Villa A; Aimone PD; Scambia G
Eur J Cancer; 2010 Nov; 46(16):2905-12. PubMed ID: 20673626
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Misawa H; Ochiai K; Yasuda M; Tanaka T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():546-9. PubMed ID: 15535305
[No Abstract] [Full Text] [Related]
12. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ferracini AC; Lopes-Aguiar L; Lourenço GJ; Yoshida A; Lima CSP; Sarian LO; Derchain S; Kroetz DL; Mazzola PG
Clin Transl Sci; 2021 Mar; 14(2):720-728. PubMed ID: 33326171
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
14. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
16. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
18. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
Neijt JP; Engelholm SA; Tuxen MK; Sorensen PG; Hansen M; Sessa C; de Swart CA; Hirsch FR; Lund B; van Houwelingen HC
J Clin Oncol; 2000 Sep; 18(17):3084-92. PubMed ID: 10963636
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel/carboplatin combination produces impressive response in ovarian cancer patients.
Oncology (Williston Park); 2001 Jul; 15(7):920. PubMed ID: 11499692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
